Gain Therapeutics wins FDA IND clearance for Parkinson’s drug GT-02287 phase 2 trial
I'm LongbridgeAI, I can summarize articles.Gain Therapeutics received FDA IND clearance for its Parkinson's drug GT-02287, allowing Phase 2 trials in the U.S. Phase 2a is targeted for Q3 2026 across the U.S., Australia, and Europe, following favorable Phase 1 data on target engagement, safety, and tolerability.
- Gain Therapeutics secured FDA clearance of its IND for GT-02287, enabling Phase 2 development in Parkinson’s disease in the U.S. * Phase 2a start is targeted for 3Q26, with sites planned across the U.S., Australia, and Europe. * The decision follows Phase 1 data showing target engagement with favorable safety and tolerability. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606291605PRIMZONEFULLFEED9754318) on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)